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Abstract
Background: RNA interference (RNAi) has become a powerful means for silencing target gene
expression in mammalian cells and is envisioned to be useful in therapeutic approaches to human
disease. In recent years, high-throughput, genome-wide screening of siRNA/miRNA libraries has
emerged as a desirable approach. Current methods for constructing siRNA/miRNA expression
vectors require the synthesis of long oligonucleotides, which is costly and suffers from mutation
problems.
Results: Here we report an ingenious method to solve traditional problems associated with
construction of siRNA/miRNA expression vectors. We synthesized shorter primers (< 50
nucleotides) to generate a linear expression structure by PCR. The PCR products were directly
transformed into chemically competent E. coli and converted to functional vectors in vivo via
homologous recombination. The positive clones could be easily screened under UV light. Using this
method we successfully constructed over 500 functional siRNA/miRNA expression vectors.
Sequencing of the vectors confirmed a high accuracy rate.
Conclusion: This novel, convenient, low-cost and highly efficient approach may be useful for high-
throughput assays of RNAi libraries.
Background
Rapid gene silencing by means of RNA interference
(RNAi) has become a powerful way of studying the func-
tion of genes on a genome-scale in cultured mammalian
cells [1-3]. High-throughput assays of RNAi libraries have
facilitated the search for genes required for diverse biolog-
ical processes, thus allowing stepwise dissection of spe-
cific signaling pathways and of the regulation of gene
function [4]. RNAi has been applied to genome-wide
reverse genetics in Caenorhabditis elegans [5]. The problem
of long (> 30 nucleotides, nt) double-stranded RNAs
(dsRNAs) eliciting interferon responses in higher verte-
brates has been conquered by the finding of short (21–23
nt) dsRNAs [6]. The RNAi response in mammalian cells
mediated by dsRNA is a well-known two-step process
[7,8]. Initially, the dsRNA is cleaved by an RNase III-like
enzyme known as Dicer, which processes dsRNA into
~22-nt small interfering RNAs (siRNAs). Then the duplex
siRNAs are passed to the RNA-induced silencing complex
(RISC), which is activated by unwinding of the duplex.
Activated RISC complexes can regulate gene expression at
many levels [9,10].
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Several approaches can be used to induce gene silencing.
The chemical synthesis method is commonly used, but it
is very expensive [11]. The limited capacity of in vitro tran-
scribed siRNA and unknown available siRNA digested by
long dsRNA (200–1000 bp with the T7 promoter) with
RNase III/Dicer limit the application of these methods
[12-15]. An alternative approach that has attracted consid-
erable interest is the generation of short hairpin RNA
(shRNA) by transfecting a plasmid or transducing a viral
vector encoding an shRNA driven by an RNA polymerase
III promoter (U6, H1, 7SK and tRNA promoters) or
polymerase II promoter (CMV or SP-C) [16-21]. shRNA,
which consists of short inverted repeats linked by a small
loop sequence, can be processed into 19–22-nt siRNA in
cells that may suppress expression of the target gene
[22,23]. Studies have demonstrated that the gene silenc-
ing effect induced by transfection of shRNA expression
vectors is comparable to that induced by chemically syn-
thesized siRNA. Furthermore, several advantages of
shRNA expression vectors mean that this approach is very
suitable for inducing gene silencing. First, the method is
fairly inexpensive. It also solves the problem of long-term
target gene suppression in cells and whole organisms.
Finally, shRNA expression cassettes of vectors can be sta-
bly integrated into the host genome using viral systems
[23,24].
A typical strategy for the construction of shRNA expres-
sion vectors in mammalian cells requires synthesis,
annealing and ligation of two long complementary oligo-
nucleotides consisting of the whole shRNA with a termi-
nal signal of 5–6 nt and extra nucleotides for cloning [25].
This method suffers from mutation of long oligonucle-
otides, and synthesis and purification of both oligonucle-
otides are costly. Many other methods can be used to
reduce the mutation problem, but most of them require at
least one long oligonucleotide, which is costly, or special
processing [26-30].
Here we report an efficient and inexpensive method for
the generation of shRNA expression vectors for in vitro
transcription that is based on one-step PCR and homolo-
gous recombination. Recently, primers with only 9 nt
complementary to the template have been subjected to
PCR and the products or plasmid fragments with homol-
ogous regions can subsequently automatically recombine
in vivo [31]. Therefore, it should be possible to construct
shRNA expression vectors by transforming PCR products
into chemically competent cells, using a convenient pro-
cedure to screen for positive clones under UV light
[32,33]. The approach can be used to produce many dif-
ferent shRNA expression vectors. Using this method, we
have constructed 442 shRNA expression vectors, most of
which were correctly sequenced. We have also constructed
119 microRNA expression vectors using the same
approach. Our results demonstrate that this is a useful
approach for constructing siRNA/miRNA expression vec-
tors at a greatly reduced cost with high efficiency and has
potential for establishing siRNA/miRNA libraries.
Results
Construction of negative control vectors
pGsilG (Figure 1A) and CMV-Gmir30/155G (Figure 1B)
were constructed based on pGenesil1.0 (Genesil Biotech-
nology Co. Ltd.) and the T-vector (TaKaRa), respectively.
The vectors were used as negative controls for screening
shRNA/miRNA expression vectors in E. coli and for cell
transfection. EGFP driven by eukaryotic promoter CMV IE
can express green fluorescence in HEK293T or HeLa cells
but not express in E. Coli. The green fluorescence protein
(GFP) cassette can be expressed in E. coli and clones
exhibit green fluorescence under UV light, so that it is easy
to screen positive clones. Since the GFP cassette is not
present in the PCR product sequence, after product trans-
formation into competent E. coli cells positive clones are
white and negative clones exhibit green fluorescence
under UV light (Figures 2 and 3). In our experiments two
or three positive clones were usually selected for auto-
mated sequencing.
The pGsilG plasmid has a hU6 promoter that drives
shRNA expression and a CMV IE promoter that drives
EGFP expression in eukaryotic cells. The CMV-Gmir30/
155G plasmid has a CMV IE promoter that drives both
miRNA and EGFP expression in eukaryotic cells. EGFP
expression provides a visual indication of the transfection
efficiency.
Illustrations of the features of pGsilG (A) and CMV-Gmir30/ 155G (B) Figure 1
Illustrations of the features of pGsilG (A) and CMV-
Gmir30/155G (B). pGsilG is constructed based on the 
shRNA expression vector pGenesil1.0. A GFP cassette is 
inserted between hU6 promoter and SV40 polyA. CMV-
Gmir30/155G is constructed based on T-vector. A miRNA 
expression cassette (CMV IE-EGFP-mir30/155 5' flank-GFP 
cassette-mir30/155 3' flank-SV40 polyA) is inserted in MCS. 
EGFP driven by CMV IE promoter is fused with GFP cassette 
and this feature will turn to the result of EGFP-miRNA fusion 
structure.BMC Biotechnology 2009, 9:53 http://www.biomedcentral.com/1472-6750/9/53
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Main procedures for the one-step PCR process Figure 2
Main procedures for the one-step PCR process. First, an appropriate PCR system and program should be adopted (A). 
Then the PCR products need to be authenticated and purified (B). After testing and purification, the PCR products can be 
transformed into chemically competent E. coli (C). Finally, positive clones (Db) are easily selected because negative clones (Da) 
exhibit green fluorescence under UV light.BMC Biotechnology 2009, 9:53 http://www.biomedcentral.com/1472-6750/9/53
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Schematic diagram of the one-step PCR process Figure 3
Schematic diagram of the one-step PCR process. (D) shows the target structure: hU6 promoter-sense-loop-anti-sense-
TTTTTT-SV40 polyA. The two panes indicate the primer sequences. The primer sequences are shown in (A). PCR then yields 
the linear vector shown in (B). It is obvious that a homologous region on each side, as shown in (C). Product transformation 
into chemically competent E. coli cells yields the structure shown in (D).BMC Biotechnology 2009, 9:53 http://www.biomedcentral.com/1472-6750/9/53
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Construction of shRNA/miRNA expression vectors
Primer design is extremely important for PCR (Figure 3A).
The primer sequences should be as follows: forward
primer, 5'-loop region-anti-sense-TTTTTT-SV40 annealing
region-3'; reverse primer, 5'-homologous region (comple-
mentary to loop) -anti-sense-hU6 annealing region-3'.
Here 9-nt loop sequences are adopted as the homologous
region. The annealing temperature depends on the length
of the hU6 and SV40 annealing primer sequences. In the
present study, 11–15 nt length of the hU6 or SV40 anneal-
ing primer sequences and an appropriate annealing tem-
perature were chosen. The primers' 5' loop regions need at
least 9 nt complementary to each other, which is sufficient
for in vivo recombination in chemically competent E. coli
(> 1 × 108 cfu/μg DNA).
The PCR program is also crucial for successful experi-
ments. In our experience, the PCR conditions are rela-
tively standard for all shRNA/miRNA genes because the
regions complementary to the template do not change. In
the present study, the conditions for KOD-Plus Taq
polymerase were as follows: 15 s at 94°C, 30 s at 38°C
and 5 min at 68°C for 25 cycles. Pfu DNA polymerase was
occasionally used with conditions as follows: 30 s at
95°C, 30 s at 40°C and 5 min at 72°C for 25 cycles.
All the PCR products should be authenticated and then
purified. Gel extraction can reduce the template back-
ground. Alternatively, the solution reclaiming method is
also suitable, for which Montage™ PCR centrifugal filter
devices (Millipore) and ethanol precipitation were used in
the present study. Then purified PCR products were trans-
formed into chemically competent E. coli cells directly. All
of the steps were completed within 8 h. The mechanism
for recombination of PCR products in vivo is not clear, but
we assumed that this occurs in line with homologous
recombination theory and that the cell repair system plays
an important role.
Sequencing of positive clones
In our research, two or three positive clones were usually
randomly selected for automated sequencing. The accu-
racy was satisfactory: only 55 out of 442 shRNA and 18
out of 119 miRNA expression plasmids contained a muta-
tion. These results indicate that our method is less error-
prone that common approaches, which have a mutation
rate of 25–50%.
RT-PCR and Western blotting
We present some representative RT-PCR and Western blot
results for SPOP (Homo sapiens speckle-type POZ protein,
GI:56119172), EGFP (Enhanced Green Fluorescence pro-
tein), p53 (Homo sapiens tumor protein p53,
GI:120407067) and Firefly luciferase (Photinus pyralis fire-
fly luciferase, GI:197215837) RNAi in Figure 4. The tar-
gets selected are shown in table 1 and the primers used in
RT-PCR are listed in table 2. We constructed these shRNA/
miRNA expression vectors using one-step PCR and tested
their interference ability in HEK293T cells. The results in
Figure 4 demonstrate that these expression vectors are effi-
cacious. The plasmids flag-SPOP, flag-EGFP and flag-fire-
fly combine the SPOP, EGFP and firefly luciferase genes
with the FLAG tag so that these proteins can be detected
using an anti-Flag antibody.
Discussion
A GFP cassette was inserted into the normal shRNA
expression vector pGenesil1.0 between the hU6 promoter
and SV40 polyA. A CMV-Gmir30/155G vector was also
constructed with the GFP cassette between the CMV pro-
moter and SV40 polyA. The GFP cassette can be expressed
in prokaryotic cells such as E. coli because it has a prokary-
otic promoter itself and is thus an outstanding screening
label, making it much simpler to screen recombinants.
The cassette is eliminated after the PCR process and thus
recombinants do not exhibit green fluorescence under UV
light after product transformation into E. coli cells. Posi-
tive clones can then be directly selected for sequencing.
Since the whole vector is reproduced in the PCR proce-
dure, DNA polymerase of high quality and fidelity should
be used. Use of poor Taq/DNA polymerase can result in
unsatisfactory transfection in spite of the correct shRNA
sequences, because eukaryotic expression components
might mutate during PCR. Thus, KOD-Plus Taq polymer-
ase (Toyobo) and Pfu DNA polymerase (Promega) were
used in our experiments and yielded satisfactory results.
The error rates of these polymerases are approximately 1.3
× 10-6 per bp duplicated. Therefore, under the condition
of 25 amplification cycles, approximately 1.1% of the
products would include mutations in the hU6 hairpin
region and 2.2% of the products may include mutations
in the CMV hairpin region. These low-probability events
Table 1: The RNAi targets used in this paper.
Name Target
shSPOP1 5' TTCCAGGCTCACAAGGCTATC 3'
shSPOP2 5' CTATCATGCTTCGGATGTC 3'
shP53 5' GACTCCAGTGGTAATCTAC 3'
mirP53 5' AGACTCCAGTGGTAATCTA 3'
mir-EGFP 5' GGCGATGCCACCTACGGCAAG 3'
sh-firefly 5' AAGCGCTATGGGCTGAATACA 3'
mir-firefly 5' AATACAAACCATCGGATCGTG 3'BMC Biotechnology 2009, 9:53 http://www.biomedcentral.com/1472-6750/9/53
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would not affect the transfection experiment. In this
method, since the whole vector is amplified by PCR, there
is a possibility that some mutations may be inserted
somewhere in the vector, even if using high-fidelity
enzyme. But in our research, no such mutations caused by
this possibility have been found. The problem could be
avoided by performing a homology search: the loop and
target sequences should not be homologous with the vec-
tor skeleton. Furthermore, the primers' annealing regions
which are complementary to the template are predesigned
and unchanged when using the same vector skeleton so
that the problem rarely happens. For example, when using
pGsilG as PCR model, the forward primer's annealing
region is TTT TTT CCC GGG ACG and the reverse primer's
annealing region is GGA TCC CGC GTC C.
Primer quality is associated with sequence accuracy. All
primers used should be purified by PAGE. The 3'
sequences affect annealing during PCR and the 5'
sequences are related to recombination in vivo, so muta-
tion of these sites will lead to failure, with no PCR prod-
ucts or no positive clones obtained. We observed that
mutations nearly always occurred in target insertion and
deletion sequences, probably during primer synthesis.
When the quality of primers was assured, fewer mutations
occurred.
The recombination of PCR products in vivo may cause
mutations of the shRNA region. The mutation rates of E.
coli are known to be approximately 10-6, but empirical evi-
dence suggests that mutation rates in palindromic regions
of plasmids are high. This indicates that mutations in the
shRNA region are associated with the shRNA sequence, so
the target selected should follow the Tuschl rules and
avoid repeats or complex sequences. In particular, the
shRNA region is separated into two parts at the end of the
PCR product, which would reduce mutations during
recombination in vivo.
Since the screening of effective RNAi targets always
requires the preparation of more than three different
shRNA expression vectors, it is costly and time-consuming
to use normal methods when performing high-through-
put assays. The normal method also suffers from muta-
tion problems. Typically, 25–50% of cloned shRNA
constructs contain significant mutations as determined by
DNA sequencing. The mutation frequency is close to 75%
when the desired siRNA sequence is 29 nt in size. The
unreliability is in part due to errors for long oligonucle-
otides of > 50 nt. The two complementary oligonucle-
otides encoding a desired shRNA target sequence are
almost 60 nt in length. For instance, oligonucleotides
encoding 19- and 29-nt target sequences with extra
enzyme-cutting sites are 57 and 77 nt, respectively. These
oligonucleotides are hard to synthesize and are unrelia-
ble. However, in our approach the primer length is < 45 nt
so that the accuracy of positive clones is dramatically
improved. Even for miRNA expression, the primer length
can be controlled to < 48 nt in size. This design of short
primers is extremely useful for overcoming mutation
problems and it is very inexpensive and less time-consum-
ing.
Conclusion
The method proposed not only reduces costs, but is also
more efficient since no digestion or ligation procedures
are required. The entire process for formation of a linear
vector can be completed within a PCR tube, and the
recombinant clones are easily screened after transforma-
tion of the PCR products. We demonstrated an alternative
approach for construction of shRNA/miRNA vectors that
is inexpensive and highly efficient. Cost savings could be
as much as 50% for primer synthesis to DNA sequencing.
First, linear products that can be converted to siRNA/
miRNA expression vectors in competent E. coli can be gen-
erated using a one-step PCR process. Second, the design of
short primers greatly decreases mutation problems and
costs. Finally, no restriction endonuclease digestion or
DNA ligation is required, meaning that this approach can
save time and resources. Thus, this highly efficient and
reliable approach may be useful for high-throughput or
genome-wide screening of RNAi libraries.
Methods
Construction of negative control vectors by molecular 
cloning
We reconstructed pGenesil1.0 (Genesil Biotechnology
Co. Ltd.) by inserting a GFP cassette, which can be
expressed in prokaryotic cells, between the hU6 promoter
Table 2: The primers used in RT-PCR.
SPOP-F 5' GTCCTCCACCTCCGGCAGAA 3'
SPOP-R 5' GGATTGCTTCAGGCGTTTGC 3'
P53-F 5' ATGGAGGAGCCGCAGTCAGA 3'
P53-R 5' GTCTGAGTCAGGCCCTTCTGTCTT 3'
EGFP-F 5' ATGGTGAGCAAGGGCGAGGA 3'
EGFP-R 5' TTACTTGTACAGCTCGTCCATGCCG 3'
FIRE-F 5' GCCCAGCGCCATTCTACCCACTCG 3'
FIRE-R 5' TGCCGCCCTTCTTGGCCTTAATG 3'
actin-F 5' GGGAGAGCGGGAAATCGTGCGTGA 3'
actin-R 5' GATGGAGTTGAAGGTAGTTTCGTG 3'BMC Biotechnology 2009, 9:53 http://www.biomedcentral.com/1472-6750/9/53
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RT-PCR (each left panel) and Western blot (each right panel) results Figure 4
RT-PCR (each left panel) and Western blot (each right panel) results. (A) HEK293T cells were transfected with a vec-
tor encoding flag-SPOP and SPOP-specific shRNA vectors (shSPOP1 and shSPOP2) or a negative control vector (shControl). 
After incubation for 48 h, total RNAs were prepared and subjected to reverse transcription-PCR for SPOP and actin mRNAs. 
Cell lysates were subjected to western blot with anti-FLAG antibody. (B) HEK293T cells were transfected with p53-specific 
shRNA/miRNA vectors (shP53/mirP53) or a negative control vector (shControl/mirControl). Anti-p53 antibody was used. (C) 
demonstrates the RT-PCR and western blot results for EGFP gene silencing. (D) and (E) demonstrate the RT-PCR and western 
blot results for firefly luciferase gene silencing.BMC Biotechnology 2009, 9:53 http://www.biomedcentral.com/1472-6750/9/53
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and SV40 polyA. The pGenesil1.0 plasmid and GFP cas-
sette were digested using the restriction endonucleases
Hind III (TaKaRa) and BamH I (TaKaRa) and then ligated
with T4 DNA ligase (TaKaRa).
We also constructed the CMV-Gmir30/155G vector based
on the T-vector (TaKaRa) by molecular cloning. The CMV
IE promoter, EGFP, the mir30/155 flanking region, a GFP
cassette and SV40 polyA were inserted in MCS (Multiple
Cloning Sites) of the T-vector.
Construction of shRNA expression vectors
The following steps were used to construct a human U6
promoter-driven shRNA vector with a recommended loop
sequence of 5'-TTCAAGAGA-3' as proof of principle.
Step 1: Primer design
Two short primers were designed for PCR with the tem-
plate pGsilG. The sequence of the forward primer was 5'-
TTC AAG AGA N(19–23)TTT TTT CCC GGG ACG-3' and
that of the reverse primer was 5'-TCT CTT GAA N(19–
23)GGA TCC CGC GTC C-3'. The 3' annealing primer
sequences, which are complementary to the template,
could be shorter than that recommended for a lower
annealing temperature. The 5' loop sequences are neces-
sary for recombination in vivo. For instance, if the target
sequence is 5'-CCA CAC AAC CTG GTA GCA T-3', the
shRNA structure should be of the form 5'-CCA CAC AAC
CTG GTA GCA TTT CAA GAG AAT GCT ACC AGG TTG
TGT GGT TTT TT-3'.
Thus, the sequence of the forward primer should be 5'-
TTC AAG AGA ATG CTA CCA GGT TGT GTG GTT TTT
TCC CGG GAC G-3' and that of the reverse primer should
be 5'-TCT CTT GAA ATG CTA CCA GGT TGT GTG GGG
ATC CCG CGT CC-3'.
All primers were ordered as general standards and were
purified by PAGE and re-suspended in TE buffer (10 mM
Tris, pH 8.0, 1 mM EDTA) at a concentration of 20 pM/μL.
The short length of the primers (≤ 45 nt) ensures their
quality.
Step 2 PCR process
To obtain abundant and reliable products, high-quality
and high-fidelity DNA polymerase was used. In this exper-
iment, KOD-Plus Taq polymerase (Toyobo) or Pfu DNA
polymerase (Promega) was used for PCR in a volume of
50 μL, with annealing at 38°C.
Step 3 Purification of PCR products and transformation
After authentication, the PCR products were purified
using a Montage™ PCR centrifugal filter device (Milli-
pore). Then the purified PCR products were transformed
into chemically competent E. coli. The transformed cells
were spread on Luria-Bertani agar plates containing anti-
biotics and incubated at 37°C overnight. Positive clones
were selected under UV light and confirmed by automated
sequencing using the hU6 sequencing primer (5'-CCA
AGG TCG GGC AGG AAG AG-3').
Construction of miRNA expression vectors
We constructed mir30/155 miRNA expression vectors in a
parallel design. The difference depends on the primer
design. We used the internet design system BLICK™-IT
RNAi Designer (Invitrogen) to select appropriate targets.
In the case of mir30, for example, the loop sequence is 5'-
TAG TGA AGC CAC AGA TGT A-3' to obtain a structure
such as: 5'-mir30flank-(G)TAA TCC TGA AGG CTC CTC
AGA TAG TGA AGC CAC AGA TGT ATC TGA GGA CTT
CAG GAT TA-mir30flank-3'. The forward primer was 5'-
AAG CCA CAG ATG TAT CTG AGG ACT TCA GGA TTA
TGC CTA CTG CC-3'. The reverse primer was 5'-CTG TGG
CTT CAC TAT CTG AGG AGC CTT CAG GAT TAC GCT
CAC TGT CAA-3'.
Here we separated the loop sequence into two parts with
9 nt complementary to each other for recombination in
vivo.
Cell culture and transfection
HeLa and HEK293T cells were grown in DMEM supple-
mented with 10% inactive fetal calf serum (FBS), 1 mM L-
glutamine, and 100 U/mL streptomycin, and incubated at
37°C in 5% CO2.
One day before transfection, cells were plated at a density
recommended by the manufacturer of the transfection
reagent (FuGENE® HD). The target expression plasmid
and shRNA/miRNA expression plasmid were transfected
into cells according to the manufacturer's instructions.
The target expression plasmid and negative control plas-
mid were transfected as a negative control. Separate wells
were used for separate constructs. The medium was
removed and replaced with fresh growth medium 4–6 h
after transfection. The cells were incubated overnight at
37°C and harvested the next day to determine the efficacy
of silencing of the target gene.
RT-PCR analysis
RT-PCR was used to semi-quantify mRNA expression level
of genes. Briefly, total RNAs were isolated from cells using
Trizol agent (Invitrogen). Reverse transcription reactions
were performed using Superscript III reverse transcriptase
(Invitrogen) and oligo(dT) primer by following the man-
ufacturer's instruction. The mRNAs were amplified with
primers listed in table 2. As internal standard, a fragment
of human endogenous β-actin was amplified simultane-BMC Biotechnology 2009, 9:53 http://www.biomedcentral.com/1472-6750/9/53
Page 9 of 10
(page number not for citation purposes)
ously in each PCR reaction. PCR products were resolved
on a 2.0% agarose gel and the bands were visualized by
ethidium bromide staining.
Western blot analysis
The cells were harvested and lysed with lysis buffer (250
mM sucrose, 1% Triton X-100, 2 mM EDTA, 10 mM
EGTA, 50 mM Tris-HCl, pH 7.4, 200 μg/mL leupeptin).
The cell lysate (10–20 μg of protein) was separated by
SDS-PAGE and electrophoretically transferred onto a
nitrocellulose membrane (Immobion™ transfer mem-
brane, Millipore, USA). After blocking non-specific bind-
ing sites with 5% non-fat milk, the membrane was
incubated with primary antibodies for 1 h at room tem-
perature. The primary antibodies used were anti-Flag
(Sigma, 1:2000 dilution), monoclonal anti-p53 antibody
(Sigma,1:1000 dilution) and anti-actin antibody (Sigma,
1:2000 dilution). After washing, the blot was incubated
with goat anti-mouse IgG (H+L)-HRP, and immunoreac-
tive bands were visualized using a Super signal maximum
sensitivity kit (Thermo Scientific).
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